Hims & Hers Narrows 2026 Revenue Outlook, Cuts Adjusted EBITDA Guidance After Surprise Q3 Loss

Hims & Hers Health swung to an unexpected net loss in the third quarter of 2026, prompting the digital healthcare company to narrow its full-year revenue outlook and lower its adjusted EBITDA forecast, according to a social media report from Top Stock Alerts. The post, published November 10, 2026, said rising operating expenses were the driver behind both the loss and the guidance revision.

What Was Reported

According to Top Stock Alerts, Hims & Hers posted disappointing third-quarter 2026 results, with increased operating expenses pushing the digital healthcare company into an unexpected loss. In response, management narrowed its full-year financial outlook and reduced its adjusted EBITDA forecast, which the report described as a sign that expenses are weighing not just on net income but on underlying operating profitability as well.

Management attributed the loss and the narrower outlook specifically to rising operating expenses, per the same report. No further breakdown of which expense categories increased, or by how much, was provided in the available reporting.

Revenue Guidance Narrowed, Not Just Lowered

Hims & Hers reduced its full-year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion, down from its previous forecast of $3.1 billion to $3.3 billion, according to Top Stock Alerts.

Doing the arithmetic on those two ranges shows how much the guidance tightened. The prior range spanned $200 million, from $3.1 billion to $3.3 billion. The new range spans just $20 million, from $3.13 billion to $3.15 billion. At the midpoint, the previous guidance implied roughly $3.2 billion in revenue (the average of $3.1 billion and $3.3 billion), while the new guidance implies roughly $3.14 billion (the average of $3.13 billion and $3.15 billion) — a midpoint reduction of about $60 million. This is our calculation based on the two guidance ranges as reported; the company's own framing of the change was not detailed beyond the ranges themselves in available reporting.

Margin Pressure Flagged Earlier in the Year

The Q3 setback follows margin commentary management offered earlier in 2026. According to TIKR's coverage of the company's Q1 2026 earnings call, Chief Financial Officer Yemi Okupe told analysts that gross margins were expected to compress further in coming quarters, as weight loss, labs, and international expansion remained the company's primary growth vectors. Okupe reportedly characterized each of those three areas as carrying lower margin profiles than the company's longer-tenured specialties, implying that continued growth in those segments would weigh on overall profitability even as revenue expanded.

That framing offers useful context for the Q3 outcome. If weight loss, labs, and international businesses were indeed growing faster than the company's longer-tenured specialties, as Okupe described in the first quarter, a structural mix shift toward lower-margin revenue would be a plausible, though not confirmed, contributor to the profitability pressure visible in the Q3 update, alongside the rising operating expenses management cited. Available reporting does not quantify how much of the third-quarter shortfall or the EBITDA guidance cut was tied to this mix shift versus other operating costs, so this connection should be read as an informed inference rather than a confirmed causal link.

Reading the Guidance Cut

Narrowing a revenue range this sharply, from a $200 million spread down to $20 million, suggests management believes it now has tighter visibility into where the year will land, even as the midpoint moved lower. One reading is that most of the uncertainty was resolved by the third-quarter results themselves; that is an interpretation of the guidance change rather than a rationale the company provided in available reporting.

At the same time, the combination of a revenue guidance cut and a lowered adjusted EBITDA forecast indicates the pressure is not confined to the top line. If margins continue to compress in the way Okupe described for weight loss, labs, and international segments, adjusted EBITDA could remain under strain even if revenue growth persists, since a larger share of that revenue would be generated at lower profitability. This is an interpretation of the available facts, not a projection endorsed by the company.

Bottom Line

Hims & Hers entered the back half of 2026 having already flagged margin compression tied to its fastest-growing segments, per TIKR's account of the Q1 2026 call. The third-quarter loss and subsequent guidance cuts, as reported by Top Stock Alerts, suggest that pressure proved heavier than the company's earlier full-year range implied. The open questions from here are whether the tighter revenue range holds and whether adjusted EBITDA stabilizes as weight loss, labs, and international operations scale — neither of which can be answered from the information currently available.